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To the Editor: A recently published report by Takemoto
et al.1 showed nice images of amyloid deposition in the
juxtaglomerular apparatus. Although the authors attributed
hyporeninemia to the amyloid deposition in the reported
case, other conditions of the case might have contributed to
hyporeninemia; hyporeninemic hypoaldosteronism can be
seen in several conditions, including advanced age, without
the amyloid deposition.2 In these conditions, the blood
volume is usually expanded rather than depleted, and
fludrocortisone should not be used.
Hypoaldosteronism induces salt-wasting in renal distal
tubules, which can cause hyperkalemia, but with normal
renal function it typically will not induce hyperkalemia.
Hyperkalemia is commonly seen in association with renal
insufficiency, which is frequently accompanied by the volume
expansion. Therefore, the reported patient, who had
hyperkalemia with an estimated glomerular filtration ratio
of B40 ml/min per 1.73 m2, is more likely to have had the
expanded volume at the time of diagnosis. With the volume
expansion, medication that facilitates the distal tubular
delivery of chloride, such as loop diuretics, would be
appropriate, and medication that facilitates the distal tubular
sodium reabsorption, such as fludrocortisone, could have
exacerbated the volume expansion.
In addition, during treatment by fludrocortisone, serum
sodium concentration should be monitored. Hyponatremia is
a feature of renal salt-wasting; the volume depletion
stimulates anti-diuretic hormone secretion. In severe hypo-
natremia, increasing serum sodium concentration faster than
8 mmol/l per day, should be avoided to reduce the risk of
central pontine myelinolysis.3
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We read the comment by Tanemoto. with profound
interest. The writer states that hyporeninemic hypoaldos-
teronism may be because of volume expansion in our
case, and that fludrocortisones should not be used
in such a condition. Regarding the issue of volume status,
extra-cellular volume in our patient was not expanded
because edema, body weight gain (changes in body
weight were being monitored in outpatient visits), and
cardiomegaly in chest X-ray were not found. Moreover,
neither the jugular vein nor the vena cava were found
to be dilated in abdominal echography. These findings
together indicated the volume status in our patient was
not expanded in any respect. Rather, she showed
volume depletion, as evidenced by her serum uric acid
level of 7.1 mg/dl. We understand that this is a kind of
chicken and egg problem, but we are sure that she was
volume-depleted without any significant proof of volume
expansion.
The pathophysiology of the hyporeninemic hypo-
aldosteronism in our patient may need more rigorous
investigation, but we attributed it to the direct inhibition
of renin production in juxtaglomerular apparatus by
massive amyloid deposition, as can be seen in Figure 1
of our article.1 Stimulation test of renin secretion by
upright posture and furosemide might have been better
performed. Anyhow, the cause of an undetectable renin
content in our case was ascribed to the problem of the
juxtaglomerular apparatus similar to the condition,
which is associated frequently with diabetes mellitus.
Hyporeninemic hypoaldosteronism is seen mostly in
diabetes mellitus.2
As to how hyporeninemic hypoaldosteronism is treated
in clinical medicine, several measures are postulated,2,3,
and fludrocortisones seemed the reasonable drug of choice
in our case as her volume status was not depleted.
Diuretics were not administered, as she was not edematous
or showed deterioration of renal function probably
because of intravascular volume depletion. In fact,
fludrocortisone has been shown effective in patients
with hyporeninemic hypoaldosteronism.2 We successfully
used fludrocortisone to correct life-threatening hyperkale-
mia without any adverse effect. The result also supported
the idea that she was not volume-expanded, otherwise
the drug might have induced hypervolemic complications
such as peripheral edema, pulmonary edema, pleural
effusion, and even congestive heart failure. Following
fludrocortisone therapy, her serum Na concentration
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